The Wellness Brew - Issue 21

Six days ago, an FDA advisory committee recommended loosening the rules on a group of peptides that includes BPC-157, and within hours the internet decided this meant the FDA had approved them. It didn't. Peptides are having a real moment and the science underneath them is interesting, but the risks need to be considered.

First, we filtered the noise — here's what's worth knowing this week.

Xanthan gum thickens and stabilizes ice cream, yogurt, sauces, gluten-free pasta, salad dressing, and most protein powders. A new study from the Federal University of São Paulo fed it to rats daily for ten weeks and found colon inflammation, a shifted gut microbiome, and a weakened intestinal barrier. To be clear, it's a rat study, so it establishes nothing in humans and the researchers described the inflammation as mild. What gives it weight is the backstory. In 2012, 22 premature infants in the US developed severe intestinal inflammation after being fed formula thickened with xanthan gum, and at least three died. Until now that connection sat as a clinical hypothesis. The lead researcher's framing is the right one: occasional exposure probably isn't the concern, but daily cumulative intake is an open question, especially for kids and older adults who rely on thickeners to swallow. The practical takeaway: check ingredients and avoid xanthan gum where you can. — Rischiteli et al., PLOS ONE, 2026.

What your gym playlist is actually doing

A 2023 systematic review pooled 30 controlled studies on pre-task music, meaning music you listen to before or during your warm-up rather than during the work itself. It found small improvements in completion time and mean power output, a moderate improvement in peak power, and a small reduction in fatigue. The largest and most consistent effect wasn't physical, but was on how good people felt heading into the session. Benefits ran larger for recreationally active people than for trained athletes. The practical takeaway: queue the hype song during your warm-up. — Delleli et al., Frontiers in Psychology, 2023.

Glyphosate exposure in pregnancy linked to preterm birth

A study published July 14 in Environmental Pollution followed 1,450 pregnant women in New York City, measuring glyphosate in their urine at two points during pregnancy. Women with higher concentrations between weeks 18 and 25 had 35 percent higher odds of preterm birth. For spontaneous preterm birth, meaning labor that starts on its own before 37 weeks rather than being medically induced, the odds roughly doubled. This is an observational cohort study, so it shows association rather than causation. The researchers also flagged that urinary glyphosate fluctuates over time, so two samples may misclassify some participants' true exposure. Even with those caveats, it's among the largest human studies on this question and one of the few measuring at multiple points in pregnancy. Choose organic grains and produce where you can, and look for products certified Glyphosate Residue Free. — Herrera et al., Environmental Pollution, 2026.

If you spend any time around fitness, longevity, or recovery content, you've run into peptides by now. Maybe it was a podcast where someone credited BPC-157 with saving them from shoulder surgery. Maybe a buddy who started a "protocol" and won't shut up about it. Maybe it was your own search history at 11pm after a tendon injury that wasn't healing on its own.

Last week the FDA joined the conversation and the result is going to push peptides further into the mainstream than they already are. So this is a good moment to figure out what these things actually are, what people are claiming, and what we honestly don't know yet.

The topic of peptides is one that I find genuinely interesting rather than alarming. It is a good thing that we're exploring new potential therapies that can help people and the biology behind peptides is real. Some of it will likely prove out. But the gap between what's been demonstrated and what's being sold is wide, and the part that gets skipped in almost every conversation is the part I want to spend the most time on.

A peptide is a short chain of amino acids. Amino acids are the building blocks of protein, and when you link a handful of them together, you get a peptide. Link a lot more and you get a protein. That's the whole distinction. Size.

Your body makes thousands of them. Insulin is a peptide. So is oxytocin. So is ghrelin, the one that tells you you're hungry. The useful way to think about the category is as signaling molecules. They mostly don't do the work themselves. They tell cells to start doing something.

Which is why the word "peptide" is close to meaningless on its own. It covers:

Same word. Completely different risk profiles. That flattening is doing a lot of work in the marketing, so it's worth holding onto.

On July 23rd and 24th, the FDA's Pharmacy Compounding Advisory Committee voted on seven peptides. Six got recommended for the 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax. One, emideltide, was rejected. [1]

Every vote was close. BPC-157, KPV, and TB-500 each cleared 8 to 6 with one abstention. MOTS-c went 7 to 5. [2]

Two things about that vote deserve more attention than they're getting.

The first is that the committee voted against the FDA's own scientists, who had recommended against all seven on the grounds that the evidence didn't support them. [3] That's not unheard of, but it's not routine either.

The second is the composition of the panel. NBC News reported that on BPC-157, KPV, and TB-500, all eight of the committee's newly appointed members voted yes, and the six no votes came from everyone else. [4] The vote follows a push from HHS Secretary Robert F. Kennedy Jr. to expand peptide access. [5] I'll let you draw your own conclusions there, but it's worth pointing out.

Now the part that's being widely misreported: nothing is legal today that wasn't legal last week.

Three separate things are getting mashed into one story. In April, twelve peptides came off the FDA's Category 2 "do not compound" list. [6] That's step one, and it didn't authorize anything. Last week's vote is step two, and it's a non-binding recommendation. [1] Step three is formal rulemaking, which involves public comment and realistically runs into 2027. The FDA isn't obligated to follow the recommendation.

If a vendor tells you the FDA just approved BPC-157, they're either confused or counting on you to be.

BPC-157 is the headliner. It's a synthetic fragment based on a protein found in gastric juice, and it's used for tendon, ligament, and gut healing. The animal literature is substantial and consistently positive. [7] Human trial data is close to nonexistent. What exists is a handful of small studies out of private clinics, several of them published in alternative medicine journals by authors affiliated with the clinics in question.

TB-500, a fragment of thymosin beta-4, gets used for similar reasons: soft tissue repair, recovery, flexibility. Same evidence picture. It's also banned by WADA, which matters if you compete in anything tested.

CJC-1295 and ipamorelin are usually stacked together and sit in the anti-aging tier. They prompt your pituitary to release more growth hormone, which raises IGF-1. That part is real and measurable. Whether it delivers the body composition, sleep, and recovery outcomes people are after is a separate question with much thinner support. [8]

MOTS-c, epitalon, and Semax are the newer entries, and among the ones the committee just voted on. Epitalon in particular has a following in longevity circles because it activates telomerase. Its human evidence is limited to small Russian trials with real methodological problems. [8]

It's also worth acknowledging the anecdotal evidence.

You may have heard them. The Achilles that finally healed after two years. The shoulder injury that avoided surgery. The gut issues that resolved. These stories are everywhere, they come from people with no reason to lie, and they're a big part of why this market exists and why this class of drugs has exploded in popularity.

We're not going to argue with the anecdotal evidence. If your tendon healed, your tendon healed, and we're not in a position to tell you it didn't. Absence of trial data isn't proof that something doesn't work.

But here's the question we're stuck with. Sure, the peptide may have worked, but there's no information at all about what else that signal was doing while it worked. What side effects are there that aren't being studied or talked about? What are the implications of long-term use that have yet to be discovered?

Growth signals don't check what they're feeding. BPC-157 works in large part by promoting angiogenesis, the growth of new blood vessels. Injured tissue needs blood supply to repair, so that's the intended effect. But BPC-157 upregulates VEGFR2, and VEGFR2 is the dominant receptor in tumor angiogenesis. Solid tumors past a couple of millimeters can't keep growing without recruiting their own blood supply, and that pathway is how they do it. It's active in roughly half of human cancers. It's also the exact target that anti-cancer drugs were built to block. [7]

So the question is straightforward: if you have something small and undiagnosed, are you helping it?

The honest answer is that nobody knows. There's a reasonable counterargument that healing angiogenesis and tumor angiogenesis are different processes, one organized and self-limiting, the other chaotic and sustained. [9] That's a plausible hypothesis. It also hasn't been tested. No experiment has directly compared BPC-157's effect on repair angiogenesis versus tumor angiogenesis in the same model. [10] The risk is open, not established, and open risk is not the same as small risk.

IGF-1 cuts both ways. The GH secretagogues work by raising IGF-1, and epidemiological studies have linked higher circulating IGF-1 to prostate, breast, and colon cancer incidence. [11] Two caveats matter here. That data is observational, so it shows association and not causation. And it describes natural variation in IGF-1 across a population, not what happens on a peptide protocol. Worth knowing: CJC-1295's commercial development stopped after a trial participant died, though the death was ruled unrelated to the drug. [8]

Epitalon's selling point is also the concern. Telomerase activation is pitched as a longevity play, and reactivating telomerase is also one of the things cancer cells do to keep dividing. Same property, two readings, and not enough human data to know which one wins out.

Nobody is keeping score. This is a glaring issue. If you buy from a gray-market vendor and something goes sideways at year five, there's no adverse event reporting system. We know about the rare side effects of approved drugs because someone is paying attention. Here, nobody is. Which means the reassuring absence of reported problems could simply represent an absence of reporting.

Separate from whether these compounds work, there's the question of whether you're getting them or not.

A 2024 peer-reviewed study tested products bought from illegal online pharmacies selling semaglutide without a prescription. All three delivered vials claimed 99% purity on the label. Measured purity came back at 14.37%, 8.97%, and 7.7%. Endotoxin, a bacterial contaminant that causes fever and inflammation when injected, was detected in all three samples. Three other purchases were outright scams where nothing shipped. [12]

That study looked at semaglutide, not BPC-157. But it's the same vendor model, the same "research use only" labeling, the same 99% purity claims, and in some cases literally the same websites.

Testing labs that handle the broader peptide market report the same pattern. Finnrick, a Texas peptide testing lab, analyzed more than 5,000 samples across 15 different peptides from 173 vendors and found that in some cases the vials didn’t contain the compound listed at all and in other cases purity ranged from 82% to 100%. Of the 5,000 samples, 8% tested positive for endotoxins. [13]

What often gets left out of the conversation is where a lot of gray-market peptides originate. US customs data shows imports of hormone and peptide compounds from China roughly doubled to $328 million in the first three quarters of 2025, up from $164 million over the same stretch of 2024. [14] The delivery mechanism is not subtle: between December 2025 and March 2026, Customs and Border Protection officers at the Port of Cincinnati intercepted more than 300 shipping cartons from China holding roughly 5,000 individual pre-labeled peptide packages addressed to recipients across the US. [15]

Early innings.

The biology is real, the anecdotes are real, and some of these compounds may eventually earn a legitimate place in our healthcare. But it's better to be honest about the uncertainty that exists currently.

How to approach peptides: the most concerning risks here aren't the ones you'd necessarily feel. They're the ones that would take years to show up. So if you're curious, that's a reason to have a real conversation with a physician who knows your history, not a clinic that benefits from selling you on the drug.

Three things you can do this week:

1. Start with a physician.
Not the clinic selling the protocol. And bring specific questions rather than a general one: your family cancer history, when you were last screened, and whether anything in your history makes a growth signal a bad idea for you in particular. That's the conversation the risks call for. 

2. Discount anyone telling you the FDA just approved these.
Nothing changed legally last week. The vote was a non-binding recommendation, formal rulemaking runs into 2027, and the FDA isn't obligated to follow it. A vendor who frames it as approval has told you something useful about the vendor.

3. Learn what a Certificate of Analysis doesn't cover.
HPLC purity tells you what fraction of the vial is the compound on the label. It tells you nothing about endotoxins, residual solvents, or heavy metals. Purity and sterility are separate tests answering separate questions, and a certificate from an unaudited lab has nothing standing behind it. A 99% purity number and a safe injection are not the same claim.

If you found this useful, please forward it to your friends and family. If you had this forwarded to you — sign up here.

Wellness, filtered.

The Wellness Brew

Sources:

Disclaimer: The Wellness Brew is for informational purposes only and does not constitute medical advice. The content published here is not intended to diagnose, treat, cure, or prevent any disease or health condition. Always consult a qualified healthcare professional before making any changes to your diet, supplement routine, or lifestyle.